OTCMKTS:RSPI RespireRx Pharmaceuticals (RSPI) Stock Price, News & Analysis → [Webinar] Understanding Covered Calls (From OIC) (Ad) Free RSPI Stock Alerts $0.0028 0.00 (0.00%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$0.0023▼$0.003550-Day Range N/A52-Week Range$0.0006▼$0.0069Volume52.49 million shsAverage Volume18.75 million shsMarket Capitalization$2.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get RespireRx Pharmaceuticals alerts: Email Address Ad AltimetryWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some of the biggest crashes in stock market history... and perfectly played the booms in artificial intelligence, electric vehicles, and cryptocurrencies. One of their wealthiest members is even outperforming Warren Buffett.Discover where they're moving their money to now. About RespireRx Pharmaceuticals Stock (OTCMKTS:RSPI)RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Read More RSPI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RSPI Stock News HeadlinesMay 29, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 23, 2024 | investing.comRespireRx Pharmaceuticals Inc (RSPI)May 1, 2024 | morningstar.comRespireRx Pharmaceuticals Inc RSPIApril 20, 2024 | seekingalpha.comRCKT Rocket Pharmaceuticals, Inc.March 20, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryMarch 9, 2024 | proactiveinvestors.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81January 22, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsJanuary 4, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic PatientDecember 11, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business DevelopmentOctober 12, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturingOctober 12, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related ServicesAugust 30, 2023 | proactiveinvestors.comPharmaceutical cannabis sales surge, clinical trials seeing broader disease focusAugust 9, 2023 | benzinga.comRespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRxAugust 9, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating CompanyJune 24, 2023 | fool.comAlnylam Pharmaceuticals (NASDAQ: ALNY)May 24, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investmentMay 24, 2023 | finance.yahoo.comResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development CostsMay 16, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. (RSPI)April 21, 2023 | finance.yahoo.comRespireRx collaborates with University College London to study treatment options for GRIA disordersApril 20, 2023 | proactiveinvestors.comRespireRx collaborating with University College London to study treatment options for GRIA disordersApril 5, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA DisordersApril 3, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publicationsApril 3, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.March 28, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its boardMarch 28, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of DirectorsSee More Headlines Receive RSPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/19/2020Today6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:RSPI CUSIPN/A CIK849636 Webwww.respirerx.com Phone(201) 444-4947Fax949-727-3657Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,100,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,950.04% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-0.03Miscellaneous Outstanding Shares804,680,000Free Float402,100,000Market Cap$2.22 million OptionableNot Optionable Beta1.13 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Arnold S. Lippa Ph.D. (Age 77)Executive Chairman, Interim President, Interim CEO & Chief Scientific Officer Comp: $339.6kDr. Jeff Eliot Margolis (Age 68)Senior VP, CFO, Treasurer, Secretary & Director Comp: $321.6kMr. Richard D. Purcell (Age 63)Senior Vice President of Research & Development Comp: $199.86kMr. David Dickason (Age 60)Senior Vice President of Pre-Clinical Product Development Mr. Marc M. RadinControllerKey CompetitorsAltamira TherapeuticsNASDAQ:CYTOPaxMedicaNASDAQ:PXMDSycamore Entertainment GroupOTCMKTS:SEGICNS PharmaceuticalsNASDAQ:CNSPInMed PharmaceuticalsNASDAQ:INMView All Competitors RSPI Stock Analysis - Frequently Asked Questions How have RSPI shares performed in 2024? RespireRx Pharmaceuticals' stock was trading at $0.0009 at the beginning of 2024. Since then, RSPI stock has increased by 206.7% and is now trading at $0.0028. View the best growth stocks for 2024 here. Are investors shorting RespireRx Pharmaceuticals? RespireRx Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 7,500 shares, a decrease of 91.0% from the April 30th total of 83,700 shares. Based on an average trading volume of 7,232,400 shares, the days-to-cover ratio is presently 0.0 days. View RespireRx Pharmaceuticals' Short Interest. How were RespireRx Pharmaceuticals' earnings last quarter? RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) announced its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter. What other stocks do shareholders of RespireRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RespireRx Pharmaceuticals investors own include American Bio Medica (ABMC), Ballard Power Systems (BLDP), Alibaba Group (BABA), Arrowhead Pharmaceuticals (ARWR), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET), Alexion Pharmaceuticals (ALXN), Allergan (AGN) and Adamis Pharmaceuticals (ADMP). How do I buy shares of RespireRx Pharmaceuticals? Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RSPI) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| Sponsored[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan ...Crypto 101 Media| SponsoredNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RespireRx Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RespireRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.